Chronic myeloid leukaemia (CML) is a type cancer that affects the blood and bone marrow.
This report contains market size and forecasts of Chronic Myeloid Leukemia (CML) Treatment in Global, including the following market information:
Global Chronic Myeloid Leukemia (CML) Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Chronic Myeloid Leukemia (CML) Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Targeted Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Chronic Myeloid Leukemia (CML) Treatment include Novartis AG, Bristol-Myers Squibb, Teva Pharmaceuticals Industries Ltd., ARIAD Pharmaceuticals, Inc., Pfizer, Inc., Hospira, Inc., Prism Pharmaceuticals, Incyte Corporation and Bio-Path Holdings, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Chronic Myeloid Leukemia (CML) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Chronic Myeloid Leukemia (CML) Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Chronic Myeloid Leukemia (CML) Treatment Market Segment Percentages, by Type, 2021 (%)
Targeted Therapy
Chemotherapy
Radiation Therapy
Splenectomy
Stem Cell Transplant
Global Chronic Myeloid Leukemia (CML) Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Chronic Myeloid Leukemia (CML) Treatment Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinic
Others
Global Chronic Myeloid Leukemia (CML) Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Chronic Myeloid Leukemia (CML) Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Chronic Myeloid Leukemia (CML) Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Chronic Myeloid Leukemia (CML) Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis AG
Bristol-Myers Squibb
Teva Pharmaceuticals Industries Ltd.
ARIAD Pharmaceuticals, Inc.
Pfizer, Inc.
Hospira, Inc.
Prism Pharmaceuticals
Incyte Corporation
Bio-Path Holdings
Stragen Pharma SA
Otsuka Pharmaceutical Co., Ltd.